You are here

  • Home
  • Archive
  • Volume 74, Issue Suppl 2
  • AB0485 Predictive Factors for Achievement of Low Disease Activity or Remission at 52 Weeks in Switching from TNF Inhibitors to Abatacept with Background of low Dose or no Methotrexate: A Multicenter Observational Cohort Study in Japan

Article info

Article menu
Download PDFPDF
Abstracts Accepted for Publication
Rheumatoid arthritis - other biologic treatment
AB0485 Predictive Factors for Achievement of Low Disease Activity or Remission at 52 Weeks in Switching from TNF Inhibitors to Abatacept with Background of low Dose or no Methotrexate: A Multicenter Observational Cohort Study in Japan

Authors

Citation

Kojima T, Takahashi N, Kaneko A on behalf of Tsurumai Biologics Communication Registry (TBCR) , et al
AB0485 Predictive Factors for Achievement of Low Disease Activity or Remission at 52 Weeks in Switching from TNF Inhibitors to Abatacept with Background of low Dose or no Methotrexate: A Multicenter Observational Cohort Study in Japan
Annals of the Rheumatic Diseases 2015;74:1059-1060.

Publication history

  • First published June 9, 2015.
Online issue publication 
April 13, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions